NEW YORK (GenomeWeb News) – Molecular Detection today announced the completion of a $1.9 million Series B recapitalization round, which will be used to further advance its molecular diagnostic panel for methicillin-resistant Staphylococcus aureus and to develop panels for sepsis and gastrointestinal infections.
All existing investors participated in the round, including MentorTech Ventures, Robin Hood Ventures, Elm Spring Holdings, and the Mid-Atlantic Angel Group. Today's announcement is in addition to a $1.5 million financing that MDI announced in March to support development of the sepsis and GI test.
MDI's Detect-Ready MRSA Panel is for detecting MRSA and methicillin-sensitive S. aureus, and according to the Wayne, Penn.-based molecular diagnostic firm, it is the only marketed PCR-based MRSA screen that can differentiate these pathogens from other related bacteria. The test is CE-marked and available in the UK, Germany, Ireland, Switzerland, Spain, Austria, the Netherlands, Belgium, Luxembourg, Australia, and Israel. It is in late-stage development in the US, MDI said.
The Detect-Ready Sepsis and GI panels are expected to launch in the EU sometime this year.